Iron deficiency in cancer patients

Revista Brasileira de Hematologia e Hemoterapia

Volumn 38, Issue 4, 2016, Pages 325-330

  Naoum, Flávio Augusto ^a  

^a Academia de Ciencia e Tecnologia   (Brazil)

Author keywords

Anemia; Cancer; Intravenous iron; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; IRON;

ALGORITHM; BLOOD TRANSFUSION; CANCER PATIENT; DRUG FORMULATION; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; SHORT SURVEY; TRANSFERRIN BLOOD LEVEL;

EID: 84995646273     PISSN: 15168484     EISSN: 18060870     Source Type: Journal    
DOI: 10.1016/j.bjhh.2016.05.009     Document Type: Short Survey

References (30)

1. 1 Park, S., Jung, C.W., Kim, K., Kim, S.J., Kim, W.S., Jang, J.H., Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. Oncotarget 6:40 (2015), 42803–42812.
2. 2 Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:15 (2004), 2293–2306.
3. 3 Ludwig, H., Müldür, E., Endler, G., Hübl, W., Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:7 (2013), 1886–1892.
4. 4 Wang, J., Pantopoulos, K., Regulation of cellular iron metabolism. Biochem J 434:3 (2011), 365–381.
5. 5 Weiss, G., Goodnough, L.T., Anemia of chronic disease. N Engl J Med 352:10 (2005), 1011–1023.
6. 6 Goodnough, L.T., Nemeth, E., Ganz, T., Detection evaluation, and management of iron-restricted erythropoiesis. Blood 116:23 (2010), 4754–4761.
7. 7 Ludwig, H., Evstatiev, R., Kornek, G., Aapro, M., Bauernhofer, T., Buxhofer-Ausch, V., et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 127:23/24 (2015), 907–919.
8. 8 Beguin, Y., Aapro, M., Bokemeyer, C., Glaspy, J., Hedenus, M., Littlewood, T.J., Current practice in diagnosis and treatment of chemotherapy-induced anemia in five European countries – a patient record study. Blood, 116, 2010, 1512 [abstract].
9. 9 Naoum, F.A., Doenças que alteram os exames hematológicos. 1st ed., 2010, Atheneu, São Paulo, 212.
10. 10 Crawford, J., Cella, D., Cleeland, C.S., Cremieux, P.Y., Demetri, G.D., Sarokhan, B.J., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:4 (2002), 888–895.
11. 11 Aapro, M., Österborg, A., Gascón, P., Ludwig, H., Beguin, Y., Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23:8 (2012), 1954–1962.
12. 12 Rizzo, J.D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M.O., Spivak, J.L., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116:20 (2010), 4045–4059.
13. 13 NCCN, Cancer and chemotherapy-induced anemia, Version 2. 2016.
14. 14 Schrijvers, D., De Samblanx, H., Roila, F., Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21:Suppl. 5 (2010), v244–v247.
15. 15 Aapro, M.S., Link, H., September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13:Suppl. 3 (2008), 33–36.
16. 16 Toblli, J.E., Angerosa, M., Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Dev Ther 8 (2014), 2475–2491.
17. 17 Geisser, P., Burckhardt, S., The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:1 (2011), 12–33.
18. 18 Gafter-Gvili, A., Rozen-Zvi, B., Vidal, L., Leibovici, L., Vansteenkiste, J., Gafter, U., et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52:1 (2013), 18–29.
19. 19 Auerbach, M., Ballard, H., Trout, J.R., McIlwain, M., Ackerman, A., Bahrain, H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:7 (2004), 1301–1307.
20. 20 Auerbach, M., Silberstein, P.T., Webb, R.T., Averyanova, S., Ciuleanu, T.E., Shao, J., et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:9 (2010), 655–663.
21. 21 Bastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pintér, T., Suto, T.S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:10 (2008), 1611–1618.
22. 22 Hedenus, M., Birgegård, G., Näsman, P., Ahlberg, L., Karlsson, T., Lauri, B., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21:4 (2007), 627–632.
23. 23 Henry, D.H., Dahl, N.V., Auerbach, M., Tchekmedyian, S., Laufman, L.R., Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:2 (2007), 231–242.
24. 24 Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:10 (2008), 1619–1625.
25. 25 Steensma, D.P., Sloan, J.A., Dakhil, S.R., Dalton, R., Kahanic, S.P., Prager, D.J., et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29:1 (2011), 97–105.
26. 26 Luporsi, E., Mahi, L., Morre, C., Wernli, J., de Pouvourville, G., Bugat, R., Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ 15:2 (2012), 225–232.
27. 27 Steinmetz, T., Tschechne, B., Harlin, O., Klement, B., Franzem, M., Wamhoff, J., et al. Clinical experience with ferric carboxymaltose in the treatment of cancer and chemotherapy-associated anaemia. Ann Oncol 24:2 (2013), 475–482.
28. 28 Hedenus, M., Karlsson, T., Ludwig, H., Felder, M., Roubert, B., Birgegard, G., Intravenous ferric carboxymaltose as sole anemia therapy in patients with lymphoid malignancies, chemotherapy-induced anemia and functional iron deficiency. Blood, 122(21), 2013, 3439.
29. 29 Calvet, X., Gené, E., ÀngelRuíz, M., Figuerola, A., Villoria, A., Cucala, M., et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol Health Care 24:1 (2016), 111–120.
30. 30 Calleja, J.L., Delgado, S., Del Val, A., Hervás, A., Larraona, J.L., Terán, Á., et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis 31:3 (2016), 543–551.